Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033620 | 0.87 | CA12 (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL7028425 | 0.86 | KIF11 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL7027027 | 0.83 | PARP1 (0.46) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL5393113 | 0.82 | GAA (0.59) | ALDH1A1SMN1; SMN2GAAPKMGPR84 | |
| SCHEMBL6009064 | 0.80 | KIF11 (0.58) | KDM4EALDH1A1PTGESCYP2C9KIF11 | |
| SCHEMBL7026650 | 0.79 | PARP1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL7027018 | 0.79 | PARP1 (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL4104209 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL7023677 | 0.75 | PARP1 (0.44) | KDM4EALDH1A1HPGDSMN1; SMN2PARP1 | |
| SCHEMBL2731175 | 0.75 | KDM4E (0.56) | KDM4EALDH1A1HPGDPARP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0775697-B1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5994542-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0878468-A1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5756738-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0775697-A1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | KDM4E 50/4885ALDH1A1 101/4885HPGD 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.